Article

The unfolding clinical spectrum of POLG mutations.

Department of Clinical Genetics, Maastricht University Medical Centre, PO Box 5800, 6202 AZ Maastricht, The Netherlands.
Journal of Medical Genetics (Impact Factor: 5.64). 08/2009; 46(11):776-85. DOI: 10.1136/jmg.2009.067686
Source: PubMed

ABSTRACT Mutations in the DNA polymerase-gamma (POLG) gene are a major cause of clinically heterogeneous mitochondrial diseases, associated with mtDNA depletion and multiple deletions.
To determine the spectrum of POLG mutations in our Dutch patient cohort, to evaluate the pathogenicity of novel mutations, and to establish genotype-phenotype correlations.
The authors identified 64 predominantly recessive mutations in 37 patients from a total of 232 patients, consisting of 23 different mutations. The substitution p.A467T was most frequently observed (n = 23), but was as frequent in childhood cases as in adult cases. Five new pathogenic recessive mutations, p.Lys925ArgfsX42, p.R275X, p.G426S, p.A804T and p.R869Q were identified. The known dominant chronic progressive external ophthalmoplegia (CPEO) mutation p.R943H was for the first time associated with premature ovarian failure as well. In 19 patients the authors identified only a single recessive mutation, or a sequence variant with unclear clinical significance. The data substantiate earlier observations that in POLG patients a fatal status epilepticus and liver failure can be triggered by sodium valproate. It is therefore important to exclude POLG mutations before administering this treatment.
The clinical features of the patient are the most important features to select putative POLG mutation carriers and not the presence of mtDNA deletions or OXPHOS (oxidative phosphorylation) activity. The authors conclude that POLG mutations are an important cause of heterogeneous mitochondrial pathology and that more accurate genotype-phenotype correlations allow a more rapid genetic diagnosis and improved prognosis for mutation carriers.

1 Follower
 · 
283 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: Mitochondrial cytopathies (MCs) result from a genetic defect in cells that leads to reduction in energy production. This can affect any organ, especially those with high-energy consumption. The authors highlight two cases of MCs who presented with isolated ptosis. The characteristics initially suggested myasthenia gravis. Subsequently the ptosis became progressive and the diagnosis was revised to MC because mitochondrial rearrangements were found in skeletal muscle DNA. Limb muscle biopsy was conclusive in one patient, but the other patient required periocular muscle to confirm the diagnosis. MC can present in this manner because heteroplasmy of mitochondrial DNA means that not all organs will exhibit clinical manifestations.
    Neuro-Ophthalmology 12/2011; 35(5-6). DOI:10.3109/01658107.2011.615453 · 0.18 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Parkinsonian features have been described in patients with POLG1 mutations. Notwithstanding, the clin- ical expression has been revealed heterogeneous and the response to dopaminergic treatment has been document in few cases. We aim to describe the longitudinal clinical features and the treatment response of three unrelated patients with neurodegenerative parkinsonism, preceded by PEO and SANDO syn- dromes, who harbor POLG1 mutations, including two novel mutations. It was documented a sustained response to levodopa, at 3 and 8 years of follow-up of parkinsonian syndrome, and reduced striatal dopamine uptake. We review the genotypic and phenotypic spectrum of POLG1-related parkinsonism. Our observations stimulate the debate around the role of mitochondrial DNA defects in the pathogenesis of neurodegenerative parkinsonism.
    Clinical Neurology and Neurosurgery 08/2014; DOI:10.1016/j.clineuro.2014.08.020 · 1.25 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: We establish the genotype-phenotype correlations for the complete spectrum of POLG syndromes, by refining our previously described protocol for mapping pathogenic mutations in the human POLG gene to functional clusters in the catalytic core of the mitochondrial replicase, Pol γ (1). We assigned 136 mutations to five clusters and identify segments of primary sequence that can be used to delimit the boundaries of each cluster. We report that compound heterozygotes with two mutations from different clusters manifested more severe, earlier onset POLG syndromes, whereas two mutations from the same cluster are less common and generally are associated with less severe, later onset POLG syndromes. We also show that specific cluster combinations are more severe than others, and have a higher likelihood to manifest at an earlier age. Our clustering method provides a powerful tool to predict the pathogenic potential and predicted disease phenotype of novel variants and mutations in POLG, the most common nuclear gene underlying mitochondrial disorders. We propose that such a prediction tool would be useful for routine diagnostics for mitochondrial disorders. This article is part of a Special Issue entitled: 18th European Bioenergetic Conference. Guest Editors: Manuela Pereira and Miguel Teixeira.
    Biochimica et Biophysica Acta 07/2014; DOI:10.1016/j.bbabio.2014.01.021 · 4.66 Impact Factor

Full-text (2 Sources)

Download
221 Downloads
Available from
Jun 6, 2014